Scientific Sessions 2024  /  Annual Lipid Updates - 2024  /  New and Emerging Targets for Lowering LDL-Cholesterol and Triglycerides: ANGPTL3, CETP, APOC-III
Logo

American Heart Association

  26
  0

Final ID:

New and Emerging Targets for Lowering LDL-Cholesterol and Triglycerides: ANGPTL3, CETP, APOC-III

  • Kastelein, John  ( ACADEMIC MEDICAL CENTER , Amsterdam , Netherlands )
  • Ray, Kausik  ( IMPERIAL COLLEGE LONDON , London , United Kingdom )
    • Author Disclosures:
    John Kastelein: DO have relevant financial relationships ; Employee:NewAmsterdam Pharma:Active (exists now) | Kausik Ray: DO have relevant financial relationships ; Research Funding (PI or named investigator):sanofi, daiichi sankyo, ultragenix, amarin:Active (exists now) ; Individual Stocks/Stock Options:New Amsteram Pharma, Scribe, Pemi31:Active (exists now) ; Speaker:Novartis, Daiichi, Merck, AZ, Novo Nordisk, BI, Sanofi, Amgen,:Active (exists now) ; Consultant:Kowa, Bayer,:Past (completed) ; Consultant:novartis, daiichi sankyo, AZ, MSD, Esoerion, Scribe, Silence Therapeutics, Cleerly, Nodthera, New Amsterdam Pharma, Amgen, Sanofi, Novo Nordisk, AZ,:Active (exists now) ; Research Funding (PI or named investigator):amgen:Past (completed)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Annual Lipid Updates - 2024

Sunday, 11/17/2024 , 08:00AM - 09:15AM

Cardiovascular Seminar

More abstracts on this topic:
Lipoprotein(a): Modifiable Risk Factor, Update in Targeted Therapies

Yeang Calvin, Bhatia Harpreet, Mehta Anurag

Controversies in Nutrition and Lipids

Anderson Cheryl, Polonsky Tamar

More abstracts from these authors:
How Low and How Fast Should We Go with LDL-Cholesterol?

Ray Kausik, Lloyd-jones Donald, Tokgozoglu Lale

Meet the Trialist: ZODIAC: Pragmatic Randomized Controlled Trial of a Decision Support System to Aid Physician Optimization of Early Lipid Lowering Therapies after Acute Coronary Syndrome

Ray Kausik

You have to be authorized to contact abstract author. Please, Login
Not Available